Stock Analysis

BIOTON Full Year 2024 Earnings: zł0.18 loss per share (vs zł0.026 profit in FY 2023)

WSE:BIO
Source: Shutterstock

BIOTON (WSE:BIO) Full Year 2024 Results

Key Financial Results

  • Revenue: zł207.8m (up 14% from FY 2023).
  • Net loss: zł15.7m (down from zł2.28m profit in FY 2023).
  • zł0.18 loss per share (down from zł0.026 profit in FY 2023).
earnings-and-revenue-history
WSE:BIO Earnings and Revenue History February 8th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

BIOTON's share price is broadly unchanged from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for BIOTON that you should be aware of.

Valuation is complex, but we're here to simplify it.

Discover if BIOTON might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About WSE:BIO

BIOTON

A biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally.

Flawless balance sheet and slightly overvalued.

Community Narratives

Priced for AI perfection - cracks are emerging
Fair Value US$90.15|44.027% overvalued
ChadWisperer
ChadWisperer
Community Contributor
NVDA Market Outlook
Fair Value US$341.12|61.937% undervalued
NateF
NateF
Community Contributor
Karoon Energy (ASX:KAR) - Buy Baby Buy 🚀
Fair Value AU$5.10|70.294% undervalued
StockMan
StockMan
Community Contributor